Incyte raises 2026 net sales forecast to $5.21 billion-$5.3 billion
INCY•Incyte raised its 2026 net sales forecast to $5.21 billion-$5.3 billion from $5.13 billion-$5.26 billion. Third-quarter net sales rose 14% to $1.32 billion.
1. Updated forecast
Incyte raised its 2026 Opzelura sales guidance to $1.1 billion-$1.12 billion from $1.05 billion-$1.1 billion and its hematology and oncology sales projection to $890 million-$910 million from $860 million-$890 million. Jakafi sales guidance remained unchanged at $3.22 billion-$3.27 billion. Third-quarter sales excluding Jakafi increased 37% to $490 million.
